A paper authored by Dr Josep Prous, Vice President of Prous Institute for Biomedical Research, published in Japan’s CBI Journal describes the advances in information technologies which allow complex data scenarios to be analyzed, and highlights the development of predictive models which correlate the features of small molecule with properties of pharmacological interest, including therapeuti...

Prous Institute has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting   "Future outlook of in silico drug discovery: Collaboration of simulation, structural biology and big data for innovative drug discovery" which takes place in Tokyo, Oct. 24-27, 2016.    During the Focused Session "Computational toxicology related topics" (Weds Oct. 26, 1...

12 May 2016. Prous Institute will be exhibiting at the 17th Drug Discovery Summit and 4th Discovery Chemistry & Drug Design Congress, 13-14 June 2016. At the exhibition, the latest version of our predictive analytics platform, Symmetry, and Global Mechanism of Action (GMoA) pharmacological profiling tool will be presented. In a single predictive model, Symmetry GMoA screens over 1,000 m...

Barcelona, Spain:  Prous Institute for Biomedical Research (PIBR) has announced today a research collaboration with the Broad Institute of MIT and Harvard implementing novel computational target action prediction methods to develop mechanistic hypotheses for small molecules. As part of the research plan Prous Institute will use their proprietary computational methods to predict targets fo...

Prous Institute has been invited to speak at the 136th Annual Meeting of the Pharmaceutical Society ofJapan (March 26-29, 2016) to be held at the Pacifico Yokohama Conference Center. The Pharmaceutical Society of Japan promotes the development of pharmaceutical sciences among its more than 20,000 members, which include chemists, physicists, biologists, and a wide profile of life science speci...